^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    TNIP2 (TNFAIP3 Interacting Protein 2)

    i
    Other names: TNIP2, TNFAIP3 Interacting Protein 2, FLIP1, Fetal Liver LKB1-Interacting Protein, TNFAIP3-Interacting Protein 2, ABIN-2, ABIN2, KLIP, A20-Binding Inhibitor Of NF-Kappa-B Activation 2, A20-Binding Inhibitor Of NF-KappaB Activation-2, MGC4289
    1year
    Icariside II Alleviates Chondrocyte Inflammatory Injury by Inhibiting the TNIP2/NF-κB Pathway. (PubMed, Cell Biochem Biophys)
    TNIP2-siRNA revealed that the TNIP2/NF-κB signaling pathway influenced the alleviating effects of icariside II on OA. In conclusion, our results revealed that icariside II attenuated IL-1β-induced inflammatory injury in chondrocytes by increasing TNIP2 expression and inhibiting NF-κB pathway activation, highlighting its therapeutic potential for OA.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • TNFAIP3 (TNF Alpha Induced Protein 3) • IL1B (Interleukin 1, beta) • TNIP2 (TNFAIP3 Interacting Protein 2)
    1year
    LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of PD-L1 protein in non-small cell lung cancer. (PubMed, J Immunother Cancer)
    LKB1 and Skp2 are required for intact PD-L1 protein expression and TME remodeling in NSCLC. Inhibition of Skp2 resulted in a conversion from "hot" TME to "cold" TME and abrogated therapeutic outcomes of immunotherapy. Screening LKB1 and Skp2 status would be helpful to select recipients who may benefit from anti-PD-1/PD-L1 immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • STK11 (Serine/threonine kinase 11) • TNIP2 (TNFAIP3 Interacting Protein 2) • SKP2 (S-phase kinase-associated protein 2)
    |
    PD-L1 expression • STK11 mutation
    over2years
    TNFAIP3 interacting protein 2 relieves lipopolysaccharide (LPS)-induced inflammatory injury in endometritis by inhibiting NF-kappaB activation. (PubMed, Immun Inflamm Dis)
    TNIP2 alleviated endometritis by inhibiting the NF-κB pathway, suggesting a potential therapeutic target for endometritis.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • TNFAIP3 (TNF Alpha Induced Protein 3) • CASP3 (Caspase 3) • IL1B (Interleukin 1, beta) • TNIP2 (TNFAIP3 Interacting Protein 2) • CAT (Catalase)